1.	Enzastaurin Versus Lomustine in Glioblastoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9817, H6Q-MC-JCBF, NCT00295815
2.	PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9823, H6Q-MC-JCBJ, PRELUDE, NCT00332202
3.	Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9815, H6Q-MC-S008, NCT00402116
4.	A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11183, H6Q-MC-S030, NCT00452413
5.	Phase II Study of LY317615 in Patients With Recurrent High-Grade Gliomas Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-03-C-0018, NCT00052663
6.	Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 8360, H6Q-MC-JCAO, NCT00088205
7.	Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 8670, H6Q-MC-JCAQ, NCT00105092
8.	Enzastaurin for Patients With Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9098, H6Q-MC-JCAR, NCT00192114
9.	Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Patients With Advanced or Metastatic Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10463, H6Q-US-S002, NCT00267020
10.	First Line Chemotherapy Treatment of Advanced NSCLC Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10651, H6Q-US-S004, NCT00308750
11.	An Open Label Study of Oral Enzastaurin in Patients With Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10287, H6Q-MC-S001, NCT00309140
12.	Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10517, H6Q-MC-S015, NCT00386087
13.	Phase II Study of Enzastaurin Hydrochloride in Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0170J, LILLY-H6Q-MC-S025, NCT00407758
14.	Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10708, H6Q-MC-S019, NCT00391118
15.	A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers Phase: Phase II Type: Prevention Status: Completed Age: 45 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10723, H6Q-MC-S009, MCC-14787, MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816, NCT00414960
16.	Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10710, H6Q-MC-S020, NCT00415363
17.	Phase 2 Trial of Enzastaurin in Prostate Cancer in Patients Who Have Had Hormonal and Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10737, H6Q-MC-S024, NCT00428714
18.	Chemotherapy for Patients With Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: 9819, H6Q-MC-S013, NCT00436280
19.	A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10538, H6Q-MC-S018, NCT00437268
20.	An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9824, H6Q-MC-S028, NCT00451178
21.	Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10736, H6Q-MC-S023, NCT00451555
22.	A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11311, H6Q-MC-S032, NCT00466440
23.	A Study of Enzastaurin in Patients With Follicular Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 8671, H6Q-MC-S011, NCT00475644
24.	A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 4849, H6Q-MC-JCAI, UCLA-0210010, LILLY-H6Q-MC-JCA, CWRU-080213J, LILY-1402, UNMC-18502, NCT00042666
25.	Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Patients With Newly Diagnosed Glioblastoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11491, H6Q-MC-S039, NCT00509821